Respiratory diseases impose an immense worldwide health burden. Five of these diseases are among most common causes of severe illness and death worldwide.
65
Million people estimated to have moderate to severe COPD
334
Million people suffer from Asthma; the number is rising
$71
Billion to $167 billion are on treating respiratory tract infections annually
We aim to impact the 14.1% of deaths in under-fives caused by pneumonia by offering a complete and globally accessible diagnostic and treatment package.
Stethee
The advent of deep neural network learning has paved the way for diagnostic hardware and artificial intelligence to provide serious support to healthcare practitioners to better diagnose respiratory diseases faster, more accurately and more effectively.
Stethee is arguably the most Intelligent, Versatile, and Powerful Stethoscope ever created. This handheld device captures collective data over time helping to unlock patterns of disease that could not be captured by a traditional stethoscopes.
Amox-DT
Approved format for 1st line treatment of Community Acquired Pneumonia (CAP) in 2-59 month old children. The dispersible tablet format allows for improved compliance.
As part of our ongoing fight against this disease, we continue to explore novel, evidence-based products and concepts; working with like-minded inventors and partners to get the right treatments to the people in need, when they need them.
Currently, we are focusing on products in the following areas.